Follow
Eldon Spackman
Eldon Spackman
Verified email at ucalgary.ca
Title
Cited by
Cited by
Year
Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold.
K Claxton, S Martin, M Soares, N Rice, E Spackman, S Hinde, N Devlin, ...
Health Technology Assessment (Winchester, England) 19 (14), 1, 2015
8132015
Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer's disease
LM Bloudek, DE Spackman, M Blankenburg, SD Sullivan
Journal of Alzheimer's Disease 26 (4), 627-645, 2011
2942011
The Transfusion Alternatives Preoperatively in Sickle Cell Disease (TAPS) study: a randomised, controlled, multicentre clinical trial
J Howard, M Malfroy, C Llewelyn, L Choo, R Hodge, T Johnson, S Purohit, ...
The Lancet 381 (9870), 930-938, 2013
2032013
Optimising the diagnosis of prostate cancer in the era of multiparametric magnetic resonance imaging: a cost-effectiveness analysis based on the prostate MR imaging study (PROMIS)
R Faria, MO Soares, E Spackman, HU Ahmed, LC Brown, R Kaplan, ...
European urology 73 (1), 23-30, 2018
1472018
Acupuncture and counselling for depression in primary care: a randomised controlled trial
H MacPherson, S Richmond, M Bland, S Brealey, R Gabe, A Hopton, ...
PLoS medicine 10 (9), e1001518, 2013
1402013
Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development
K Claxton, S Palmer, L Longworth, L Bojke, S Griffin, C McKenna, ...
NIHR Health Technology Assessment Programme, 2012
1192012
Tumour necrosis factor-α inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation
M Corbett, M Soares, G Jhuti, S Rice, E Spackman, E Sideris, ...
Health technology assessment 20 (9), 333, 2016
892016
The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective
JD Campbell, DE Spackman, SD Sullivan
Allergy 65 (9), 1141-1148, 2010
892010
Bidirectional citation searching to completion: an exploration of literature searching methods
S Hinde, E Spackman
Pharmacoeconomics 33 (1), 5-11, 2015
832015
Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study.
LC Brown, HU Ahmed, R Faria, AES Bosaily, R Gabe, RS Kaplan, ...
Health technology assessment (Winchester, England) 22 (39), 1, 2018
752018
Acupuncture for chronic pain and depression in primary care: a programme of research
H MacPherson, A Vickers, JM Bland, DJ Torgerson, MS Corbett, ...
Programme Grants for Applied Research, 1-342, 2017
752017
The adverse health effects and harms related to marijuana use: an overview review
KA Memedovich, LE Dowsett, E Spackman, T Noseworthy, F Clement
Canadian Medical Association Open Access Journal 6 (3), E339-E346, 2018
682018
Dependence as a unifying construct in defining Alzheimer's disease severity
T McLaughlin, H Feldman, H Fillit, M Sano, F Schmitt, P Aisen, C Leibman, ...
Alzheimer's & Dementia 6 (6), 482-493, 2010
642010
Effect of information and telephone-guided access to community support for people with chronic kidney disease: randomised controlled trial
T Blakeman, C Blickem, A Kennedy, D Reeves, P Bower, H Gaffney, ...
PloS one 9 (10), e109135, 2014
572014
Systematic review of the cost and cost-effectiveness of rapid endovascular therapy for acute ischemic stroke
LK Sevick, S Ghali, MD Hill, V Danthurebandara, DL Lorenzetti, ...
Stroke 48 (9), 2519-2526, 2017
502017
A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis B
DE Spackman, DL Veenstra
Pharmacoeconomics 26 (11), 937-949, 2008
462008
Assessing the value of screening tools: reviewing the challenges and opportunities of cost-effectiveness analysis
N Iragorri, E Spackman
Public health reviews 39 (1), 1-27, 2018
452018
A comprehensive algorithm for approval of health technologies with, without, or only in research: the key principles for informing coverage decisions
K Claxton, S Palmer, L Longworth, L Bojke, S Griffin, M Soares, ...
Value in Health 19 (6), 885-891, 2016
452016
Measuring Alzheimer disease progression with transition probabilities: estimates from NACC-UDS
DE Spackman, S Kadiyala, PJ Neumann, DL Veenstra, SD Sullivan
Current Alzheimer research 9 (9), 1050, 2012
452012
Evaluating anti‐viral drug selection and treatment duration in HBeAg‐negative chronic hepatitis B: a cost‐effectiveness analysis
DL Veenstra, DE Spackman, A Bisceglie, KV Kowdley, RG Gish
Alimentary pharmacology & therapeutics 27 (12), 1240-1252, 2008
422008
The system can't perform the operation now. Try again later.
Articles 1–20